Awarding a European prize is equivalent to a validation of the Technology readiness level (TRL) of the project by an independent body (EASME).
2017 H2020 SME INSTRUMENT phase-2 Topic :SMEInst-03-2017. European commission
2015 H2020 SME INSTRUMENT phase-1 Topic : BIOTEC-5a2015. European commission
2015 17th i-Lab “Créadev” BPI France
2013 15th “émergence” OSEO/BPI
2013 – Innovation Days One of 15 finalists “Innovation Prize” Universal Biotech.
Regulaxis gets confirmed the relevance of it Asian international development plans
Despite troubled times due to Covid lockdowns
After being successfully selected by EU again to get sponsored participation at “BioJapan” Expo in Yokohama, next October 2020
Regulaxis’ President Claude Carelli participated to the interview on B SMART
The 1st meeting dedicated to small and medium-sized businesses.
At the microphone of Jean-Marc Sylvestre, Claude Carelli expose Regulaxis activity, their strategy, their needs and objectives.
A program in partnership with BPI France at 1 p.m. and 8:30 p.m. on B SMART.
Regulaxis is proud to announce the publication to the In Vivo study, on rat model of traumatic knee osteoarthritis, conducted in collaboration with Artialis SA, on PLOS ONE journal.
Following evaluation by an international panel of independent experts, Regulaxis research was scored as a high-quality project proposal in a highly competitive evaluation process.
This proposal is recommended for funding by other sources, since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.
The project proposal: “REG-O3 Treatment of gonarthrosis […]
Une histoire de biotechnologies innovantes
Basé à Biocitech, le parc technologique des Sciences de la Vie, juste à côté de Paris, Regulaxis est une entreprise engagée dans la recherche, le développement et la concession de licences de molécules synthétiques innovantes destinées à être utilisées en thérapie humaine.
Sa mission est d’octroyer des licences de molécules innovantes […]
Regulaxis’ President Claude Carelli and the COO Christelle Vêtu participated to the RDV PME by Le Figaro Economie
This interview is focused on the research and development in the field of bioscience. In particular Regulaxis present a new innovative compound, REGO3, for the treatment of arthroses.
Follow the full article to Le Figaro Economie
Regulaxis is very proud to be the only French company selected by the EU-Japan Industrial Cooperation Center to be part of the European delegation !
Thank you also to Miyagi province officials and Jetro for receiving us and meeting top industrial companies in Sendai.
Dr. Matthieu Chareyre, our Executive Director of Industrial Operations, represented Regulaxis to this […]
Lors de la séance du 8 Avril du CLUB PME – ETI Claude CARELLI, Président et CEO de Regulaxis a présenté son entreprise et son « business model ». Les membres du Club l’ont « challengé » pour qu’il récolte le fruit de ce «brainstorming » collectif.
Engagée dans la R&D, Regulaxis développe des molécules […]
The offices of the Regulaxis Management Office are located at the feet of La Défense, the business district located in the Metropole du Grand Paris.
REG-O3, the innovative therapeutic treatment for Osteoarthritis will be tested in Liège !:
Artialis, specialist in the study of the musculoskeletal disorders and Regulaxis, an innovative French company in the treatment of osteoarthritis, announce today the signing of a 1.6 million euros contract for the preclinical and clinical development of a new molecule, Reg-O3, allowing […]